Biomarkers to Non-Invasively Determine the Atrial Fibrillation Progression Phenotype: A Bridge to Individualized Ablative Therapy?

Finding the adequate therapy for patients with atrial fibrillation (AF) can often feel like a never-ending challenge. Although AF represents the most common age-related, progressive cardiac arrhythmia worldwide, there still is no curative therapy. Ablative therapy seemed promising, but many patients have recurrences or require multiple ablation procedures. Pulmonary vein isolation (PVI) is like flipping a coin, as single-procedure freedom from atrial arrhythmia at long-term follow-up is only ∼50% in the overall population.

Source: Heart Rhythm - April 3, 2018 Category: Cardiology Authors: Roeliene Starreveld, Natasja M.S. de Groot Source Type: research